Hypothesis: antiplatelet effects of selective serotonin reuptake inhibitors cause clinical benefits on cardiovascular disease and increase risks of bleeding.
Serebruany
Victor L
VL
HeartDrug Research Laboratories, Johns Hopkins University, Baltimore, MD 21204, USA. heartdrug@aol.com
O'Connor
Christopher M
CM
Krishnan
Ranga R
RR
Hennekens
Charles H
CH
D002318:Cardiovascular Diseases / Q000188:drug therapy*; D006801:Humans; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D017367:Selective Serotonin Reuptake Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*
D010975:Platelet Aggregation Inhibitors; D017367:Selective Serotonin Reuptake Inhibitors